|

FOLFIRI Protocol Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: FOLinic acid-Fluorouracil-IRInotecan regimen, Zaltrap

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Neonc Technologies, Inc.1
  • Massachusetts General Hospital1

Indications

  • Cancer2
  • Mismatch Repair Deficient Colorectal Cancer1
  • Mismatch Repair Deficient Solid Malignant Tumor1
  • Diffuse Astrocytoma, IDH-Mutant1
  • Microsatellite Instability-High Colorectal Cancer1

Beverly Hills, California1 trial

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Precision NextGen Oncology

Phase 1/2

Boston, Massachusetts1 trial

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Massachusetts General Hospital

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.